

S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ROOS et al. Serial No.: Unknown  
Filed: concurrent herewith Docket No.: 05822.0319USWO  
Title: LECTIN PATHWAY DEFICIENCY ASSAY

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 407258444 US  
Date of Deposit: January 11, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

By:   
Name: James Larkin

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop PCT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: January 11, 2005

By   
John J. Gresens  
Reg. No. 33,112

JJG/acp

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 05822.0319USWO	Application Number: Unknown
	Applicant: ROOS et al.	
	Filing Date: concurrent herewith	Group Art Unit:

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,297,024 B1	10/2001	Hugli et al.			

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	02/06460 A2	01/2002	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Fredrikson et al. "New procedure for the detection of complement deficiency by ELISA: Analysis of activation pathways and circumvention of rheumatoid factor influence". <i>Journal of Immunological Methods</i> 1993, Vol. 166, pp. 263-270.
	Gupta-Bansal et al. "Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies". <i>Molecular Immunology</i> 2000, Vol. 37, pp. 191-201.
	Kuipers et al. "A hemolytic assay for the estimation of functional mannose-binding lectin levels in human serum". <i>Journal of Immunological Methods</i> 2002, Vol. 268, pp. 149-157.
	Petersen et al. "An assay for the mannan-binding lectin pathway of complement activation". <i>Journal of Immunological Methods</i> 2001, Vol. 257, pp. 107-116.
	Roos et al. "Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides". <i>The Journal of Immunology</i> 2001, Vol. 167, 7052-7059.
	Suankratay et al. "Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway". <i>The Journal of Immunology</i> 1998, Vol. 160, pp. 3006-3013.
	Zimmerman-Nielsen et al. "Complement activation mediated by mannan-binding lectin in plasma from healthy individuals and from patients with SLE, Crohn's disease and Colorectal cancer. Suppressed activation by SLE plasma". <i>Scand. J. Immunol.</i> 2002, Vol. 55, pp. 105-110.

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	